crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 716290

Zbornik radova

Autori: Režić-Mužinić, Nikolina; Mastelić, Angela; Markotić, Anita; Čikeš Čulić, Vedrana; Vuica- Ross, Milena; Ross, Ashley; Barker, David; Reynisson, Jóhannes
Naslov: The effect of a phospholipase C gamma inhibitor on the proliferation and phenotype of Du145 prostate cancer cells
Izvornik: FEBS J 281(Suppl. 1)
ISSN: 1742-4666
Skup: FEBS EMBO 2014 Conference
Mjesto i datum: Pariz, Francuska, 30.08.-04.09.2014.
Ključne riječi: prostate cancer ; phospholipase C inhibitor
Sažetak:
INTRODUCTION: Prostate cancer remains the second most common cause of cancer related death among men, highlighting the need for new therapies. Many cancer cellular functions have been discovered to be regulated by phospholipase C (PLC) gamma activation, suggesting that it represents an important therapeutic target for development of anticancer drugs. Here, we investigate the influence of a newly developed, small molecule PLC gamma inhibitor, with or without taxane therapy, on the growth and survival of sub-populations of a prostate cancer cell line. MATERIALS AND METHODS: Cells were incubated 48h with Paclitaxel (5 nM) and PLC gamma inhibitor (1 microM) alone or in their combination.The viable cells were determined by the MTT assay. Flow cytometric analysis of cells positive to anti- CD44, anti-CD54, and propidium iodide staining was performed to characterise apoptotic Du145 sub- populations 48h after inhibitor treatment. RESULTS: Treatment of the DU145 prostate cancer cell line with the PLC gamma inhibitor resulted in cell cycle arrest with minimal increase in apoptosis. Sub-populations of prostate cancer cell lines have unique phenotypes (with CD44+ cells being more proliferative and CD54+ cells serving as better CD8+ T cell targets). We examined the effects of the PLC gamma inhibitor on these subpopulations and found that exposure decreased the percentage of both CD44+ (p=0.00007) and CD54+ (p=0.009) sub-populations. In contrast, treatment with Paclitaxel only effected CD44+ cells (p=0.0002). Combination treatment of the PLC gamma inhibitor and Paclitaxel however had synergistic effects on both CD44+ and CD54+ DU145 cells (p=0.005 and p=0.0002, respectively). CONCLUSIONS: These results suggest that a combination of PLC gamma inhibitor and Paclitaxel could be a novel strategy for the treatment of prostate cancer.
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
Vrsta sudjelovanja: Poster
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Međunarodna recenzija
Projekt / tema: 216-2160133-0066
Izvorni jezik: ENG
Kategorija: Znanstveni
Znanstvena područja:
Temeljne medicinske znanosti,Farmacija
URL Internet adrese: http://onlinelibrary.wiley.com/doi/10.1111/febs.2014.281.issue-s1/issuetoc
Upisao u CROSBI: Anita Markotić (anita.markotic@mefst.hr), 22. Ruj. 2014. u 08:26 sati



Verzija za printanje   za tiskati


upomoc
foot_4